Contact   |    Careers   |    Employees   |    Physicians

Cancer Center


 
 
 

Departments

 
 
 

Cancer Center - Clinical Trials

Oncology Research Office

What is a Clinical Trial?

Clinical trials are used to test, measure, and learn more about the effectiveness and risks of new treatments. After researchers explore experimental treatments in the laboratory, those with the most promising results move into clinical trials.

What are the benefits?

Participants gain access to new treatments before they are widely available, and help others by contributing to medical research that could lead to new breakthroughs.

Who can join a trial?

Participants must qualify based on specific guidelines. Some trials seek those with illnesses or conditions being studied, others need healthy participants.

How are people protected?

Trials are designed to protect participants and keep them safe. Risks and potential benefits are carefully explained, and participants may withdraw at any time. Ethical and legal codes governing medical practice apply to clinical trials, and most are federally regulated. An independent committee of physicians, statisticians, community advocates, and others provide approval and ongoing review to protect the rights of participants. 

Clinical trials give our community access to the best research and next level of care. A recent commendation from the Commission on Cancer made particular note of the number of patients Sibley places in trials.

Please contact Amanda Moser at (202) 660-6420 or by email amoser6@jhmi.edu to learn about the clinical trials offered at Sibley.

 

Open Protocol Information

Updated April 2, 2015



Breast Cancer  

E2108   

A Randomized Phase III Trial of the Value of Early Local Therapy for the Intact Primary Tumor in Patients with Metastatic Breast Cancer

 

J0888   

Johns Hopkins Breast Cancer Program Longitudinal Repository

 

J1189   

Johns Hopkins Breast Cancer Program Hormone Therapy Longitudinal Database

 

J1232 (DIG-HIF1 PK)        

Digoxin as a Novel Inhibitor of Global Hypoxia Inducible Factor-1α (HIF-1α) Expression & Downstream Targets in Breast Cancer: DIG-HIF1 Pharmacodynamic Trial

 

J13104 (PBI)       

A Randomized Phase II Study of Partial Breast Irradiation and Sequential vs. Concurrent Chemotherapy in Women with ER Negative Early Stage Breast Cancer

 

ES1007

Phase III Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients with 1-3 Positive Nodes, Hormone Receptor-Positive and HER-2 Negative Breast Cancer with Recurrence Score (RS) of 25 or Less. RxPONDER: A Clinical Trial RX for Positive Node, Endocrine Responsive Breast Cancer

 

J1349

Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients With HER2+ Metastatic Breast Cancer Who Have Received Two or More Prior HER2-Directed Regimens in the Metastatic Setting

 

E1Z11

A Cohort Study to Evaluate Genetic Predictors of Aromatase Inhibitor Musculoskeletal Symptoms (AIMSS)

SIB1392
Combination immunotherapy with Herceptin and the HER2 vaccine E75 in low and intermediate HER2-expressing breast cancer patients to prevent recurrence


S1207
Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer

J13160
Detection and Prevention of Anthracycline-Related Cardiac Toxicity with Concurrent Simvastatin


E2112
A Randomized Phase III Trial of Endocrine Therapy plus Entinostat/Placebo in Postmenopausal Patients with Hormone Receptor-Positive Advanced Breast Cancer 

TBCRC026
Correlation of Early Changes in SUV on PET with Pathological CR to Pertuzumab and Trastuzumab in Primary Operable HER2-Pos Breast Cancer 

TBCRC030
A Randomized Phase II Study of Preoperative Cisplatin versus Paclitaxel in Patients with Triple Negative Breast Cancer without Germline BRCA Mutations: Evaluating the Homologous Recombination Deficiency (HRD) Biomarker


J1377 (ATEMPT)
A Randomized Phase II Study of Adjuvant Trastuzumab Emtansine (T-DM1) vs. Paclitaxel in Combination with Trastuzumab for Stage I HER2-positive Breast Cancer

SIB14150
Phase II Trial of Combination Immunotherapy with nelipepimut-S +GM-CSF (NeuVax) and Trastuzumab in high-risk HER2+ Breast Cancer Patients 

NSABP B55

A randomized, Double-Blind, Parallel Group, Placebo-Controlled Multi-Centre Phase III Study to Assess the Efficacy and Safety of Olaparib Versus Placebo as Adjuvant Treatment in Patients with Germline BRCA1/2 Mutations and High Risk HER2 Negative Primary Breast Cancer Who Have Completed Definitive Local Treatment and Neoadjuvant or Adjuvant Chemotherapy

 

NSABP B51

A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chestwall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients with Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy  

 

Gastrointestinal Cancer  

CALGB 80702    

A Phase III trials of 6 versus 12 treatment of Adjuvant Treatment of Adjuvant  Folfox plus Celecoxib or Placebo for patient with Resected Stage III Colon Cancer

N1048

PROSPECT: A Phase II/III trial of Neoadjuvant FOLFOX, with Selective Use of Combined Modality Chemoradiation versus Preoperative Combined Modality Chemoradiation for Locally Advanced Rectal Cancer Patients Undergoing Low Anterior Resection with Total Mesorectal Excision

 

Genitourinary Cancer  

J11157

Stereotactic Body Radiation Therapy and Short-Term Androgen Ablation for Intermediate-Risk, Localized, Adenocarcinoma of the Prostate

 

J12103 

A Randomized Gene Fusion Stratified Phase 2 Trial Of Abiraterone With Or Without ABT 888 For Patients With Metastatic Castration-Resistant Prostate Cancer (NCI# 9012)

 

J1262 (Biopsy)   

Understanding Mechanisms of Response and Resistance to Androgen-Directed Therapies in Men with Advanced Prostate Cancer Through Interrogation of Tumor Biopsies: A Pilot/Feasibility Study

 

J12135 

Development and Evaluation of Tumor Markers for Clinically Significant Prostate Cancer
  

J1409   

Immune Evaluation Study of Sipuleucel-T in African American and European American Men with Castrate Resistant Prostate Cancer

 

R0926   

A Phase II Protocol for Patients with Stage T1 Bladder Cancer to Evaluate Selective Bladder Preserving Treatment by Radiation Therapy Concurrent with Radiosensitizing Chemotherapy Following a Thorough Transurethral Surgical Re-Staging

 

S1216   

A Phase III Randomized Trial Comparing Androgen Deprivation Therapy TAK-700 With Androgen Deprivation Therapy Bicalutamide in Patients With Newly Diagnosed Metastatic Hormone Sensitive Prostate Cancer

 

J1315 (ARN-509-003)      

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase III Study of ARN-509 in Men with Non-Metastatic (M0) Castration-Resistant Prostate Cancer

 

J1332 (LCCC-1231)

Observational Longitudinal Study of Pain in Men with Metastatic Castrate-Resistant Prostate Cancer

 

J1307 (ABICURE)

Abiraterone alone, abiraterone plus degarelix, a GnRH antagonist, and degarelix alone for prostate ca w/ rising PSA or a rising PSA and nodal disease following definitive radical prostatectomy

 

J1336

Race as a Risk Factor for Metastatic Prostate Cancer: A Sentinel Event Case Series

 

J1416

A Phase II Study to Determine Sequential Response to Bipolar Androgen Therapy (BAT) followed by Enzalutamide or Abiraterone Post-BAT in Men with Prostate Cancer Progressing on Combined Androgen Ablative Therapies

 

A031201

Phase III Trial of Enzalutamide (NSC # 766085) Versus Enzalutamide, Abiraterone and Prednisone for Castration Resistant Metastatic Prostate Cancer

J1416

A Phase II Study to Determine Sequential Response to Bipolar Androgen Therapy (BAT) followed by Enzalutamide or Abiraterone Post-BAT in Men with Prostate Cancer Progressing on Combined Androgen Ablative Therapies

 

J0394

Active Surveillance of Prostate Cancer

J1380

A biospecimen bank and study to understand genitourinary cancer and other benign urologic conditions.

 
 

Gynecologic Cancer  

GOG 0263            

A Randomized Phase III Clinical  Trial of  Adjuvant Radiation Versus Chemoradiation  In Intermediate Risk, Stage I/IIA Cervical Cancer Treated with Initial Radical Hysterectomy and Pelvic Lymphadenectomy. 

 

GOG 0238            

A Randomized Trial of Pelvic Irradiation With or Without Concurrent Weekly Cisplatin In Patients with Pelvic-Only Recurrence of Carcinoma of the Uterine Corpus

 

GOG 0277            

A Phase III Randomized Trial of Gemcitabine plus Docetaxel Followed by Doxorubicin versus Observation for Uterus-Limited High-Grade Uterine Leiomyosarcoma

R0724/G0724

Concurrent Chemotherapy and Pelvic RT w/wo Adj Chemo in High-Risk Pts with Early-Stage Cervical Ca following Radical Hysterectomy 

Kidney Cancer

ECOG 1808

 

A Randomized Phase II Trial of Sunitinib/Gemcitabine or Sunitinib in Advanced Renal Cell Carcinoma with Sarcomatoid Features


Lung Cancer  

ECOG 5508         

Randomized Phase III Study of Maintenance Therapy with Bevacizumab, Pemetrexed, or a combination of Bevacizumab and Pemetrexed Following Carboplatin, Paclitaxel and Bevacizumab for Advanced Non-Squamous NSCLC 

 

SIB1301

Amgen: Evaluate the Long-Term Safety and Efficacy of Darbepoetin Alfa Administered at 500 µg Once-Every-3-Weeks in Anemic Subjects w/ Advanced Stage NSCLC Receiving Multi-Cycle Chemo

 

Leukemia/Lymphoma  

There are no open studies at this time.

Melanoma  

There are no open studies at this time.
 
 
© Copyright 2014 Sibley Memorial Hospital